Iparomlimab and tuvonralimab — Investigational Agent
Bispecific Antibody · Phase 3 · Qilu Pharmaceutical
Mechanism of Action
A dual-function antibody mixture co-targeting PD-1 and CTLA-4, combining checkpoint blockade of PD-1 with a rapidly clearing anti-CTLA-4 component intended to enhance T-cell activation while limiting immune toxicity.
Investigational Indications
- Cervical cancer
- Nasopharyngeal carcinoma
- Non-small cell lung cancer